FR2944206B1 - Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione - Google Patents

Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Info

Publication number
FR2944206B1
FR2944206B1 FR0901755A FR0901755A FR2944206B1 FR 2944206 B1 FR2944206 B1 FR 2944206B1 FR 0901755 A FR0901755 A FR 0901755A FR 0901755 A FR0901755 A FR 0901755A FR 2944206 B1 FR2944206 B1 FR 2944206B1
Authority
FR
France
Prior art keywords
therapeutic applications
cardiovascular field
quinazolinedione derivatives
quinazolinedione
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0901755A
Other languages
English (en)
French (fr)
Other versions
FR2944206A1 (fr
Inventor
Philip Janiak
Gilbert Marciniak
Jean Francois Nave
Fabrice Viviani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0901755A priority Critical patent/FR2944206B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to CN201080025111.8A priority patent/CN102458409B/zh
Priority to SG2011073459A priority patent/SG175131A1/en
Priority to PCT/FR2010/050672 priority patent/WO2010116090A1/fr
Priority to EA201171229A priority patent/EA020984B1/ru
Priority to EP10723222.5A priority patent/EP2416777B1/fr
Priority to DK10723222.5T priority patent/DK2416777T3/en
Priority to SI201030847T priority patent/SI2416777T1/sl
Priority to JP2012504056A priority patent/JP5685578B2/ja
Priority to NZ595660A priority patent/NZ595660A/xx
Priority to AU2010233596A priority patent/AU2010233596B2/en
Priority to KR1020117026562A priority patent/KR101686267B1/ko
Priority to MA34322A priority patent/MA33254B1/fr
Priority to HUE10723222A priority patent/HUE024161T2/hu
Priority to ES10723222.5T priority patent/ES2528633T3/es
Priority to PT107232225T priority patent/PT2416777E/pt
Priority to MX2011010645A priority patent/MX2011010645A/es
Priority to CA2758234A priority patent/CA2758234A1/fr
Priority to SG10201400420PA priority patent/SG10201400420PA/en
Priority to BRPI1010256A priority patent/BRPI1010256A2/pt
Priority to PL10723222T priority patent/PL2416777T3/pl
Priority to TW099110928A priority patent/TWI457330B/zh
Priority to ARP100101179A priority patent/AR076232A1/es
Priority to UY0001032555A priority patent/UY32555A/es
Publication of FR2944206A1 publication Critical patent/FR2944206A1/fr
Priority to DO2011000306A priority patent/DOP2011000306A/es
Priority to IL215610A priority patent/IL215610A/en
Priority to CR20110527A priority patent/CR20110527A/es
Priority to NI201100180A priority patent/NI201100180A/es
Priority to EC2011011377A priority patent/ECSP11011377A/es
Priority to US13/268,371 priority patent/US8846654B2/en
Priority to TNP2011000506A priority patent/TN2011000506A1/fr
Priority to CL2011002525A priority patent/CL2011002525A1/es
Priority to CO11132796A priority patent/CO6440577A2/es
Priority to HK12106684.4A priority patent/HK1165997A1/zh
Application granted granted Critical
Publication of FR2944206B1 publication Critical patent/FR2944206B1/fr
Priority to HRP20150106TT priority patent/HRP20150106T1/hr
Priority to CY20151100141T priority patent/CY1115987T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0901755A 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione Expired - Fee Related FR2944206B1 (fr)

Priority Applications (36)

Application Number Priority Date Filing Date Title
FR0901755A FR2944206B1 (fr) 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
CA2758234A CA2758234A1 (fr) 2009-04-09 2010-04-07 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
PCT/FR2010/050672 WO2010116090A1 (fr) 2009-04-09 2010-04-07 Applications thérapeutiques dans le domaine cardiovasculaire de dérivés de quinazolinedione
EA201171229A EA020984B1 (ru) 2009-04-09 2010-04-07 Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
EP10723222.5A EP2416777B1 (fr) 2009-04-09 2010-04-07 Applications thérapeutiques dans le domaine cardiovasculaire de dérivés de quinazolinedione
DK10723222.5T DK2416777T3 (en) 2009-04-09 2010-04-07 Therapeutic uses of quinazolindionderivater in the field of cardiovascular
BRPI1010256A BRPI1010256A2 (pt) 2009-04-09 2010-04-07 "aplicações terapêuticas no domínio cardiovascular de derivados de quinazolina diona."
JP2012504056A JP5685578B2 (ja) 2009-04-09 2010-04-07 キナゾリンジオン誘導体の心臓血管分野における治療適用
NZ595660A NZ595660A (en) 2009-04-09 2010-04-07 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
AU2010233596A AU2010233596B2 (en) 2009-04-09 2010-04-07 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
KR1020117026562A KR101686267B1 (ko) 2009-04-09 2010-04-07 퀴나졸린디온 유도체의 심혈관 분야에서의 치료 용도
MA34322A MA33254B1 (fr) 2009-04-09 2010-04-07 Applications thérapeutiques dans le domaine cardiovasculaire de dérivés de quinazolinedione
HUE10723222A HUE024161T2 (hu) 2009-04-09 2010-04-07 Kinazolindion-származékok terápiás alkalmazása kardiovaszkuláris területen
ES10723222.5T ES2528633T3 (es) 2009-04-09 2010-04-07 Aplicaciones terapéuticas en el campo cardiovascular de derivados de quinazolindiona
PT107232225T PT2416777E (pt) 2009-04-09 2010-04-07 Aplicações terapêuticas no domínio cardiovascular de derivados de quinazolinadiona
MX2011010645A MX2011010645A (es) 2009-04-09 2010-04-07 Usos terapeuticos en el dominio cardiovascular de derivados de quinazolinadiona.
SG2011073459A SG175131A1 (en) 2009-04-09 2010-04-07 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
SI201030847T SI2416777T1 (sl) 2009-04-09 2010-04-07 Terapevtske uporabe kinazolindionskih derivatov na kardiovaskularnem področju
CN201080025111.8A CN102458409B (zh) 2009-04-09 2010-04-07 喹唑啉二酮衍生物在制备治疗心血管领域疾病的药物中的应用
PL10723222T PL2416777T3 (pl) 2009-04-09 2010-04-07 Terapeutyczne zastosowania pochodnych chinazolinodionu w układzie sercowo-naczyniowym
SG10201400420PA SG10201400420PA (en) 2009-04-09 2010-04-07 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
TW099110928A TWI457330B (zh) 2009-04-09 2010-04-08 喹唑啉二酮衍生物於心血管領域之治療應用
ARP100101179A AR076232A1 (es) 2009-04-09 2010-04-08 Aplicaciones en terapeutica de derivados de quinazolinadiona.
UY0001032555A UY32555A (es) 2009-04-09 2010-04-09 Nuevos derivados de quinazolinadiona
EC2011011377A ECSP11011377A (es) 2009-04-09 2011-10-06 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona
IL215610A IL215610A (en) 2009-04-09 2011-10-06 Medical applications of @ kinazolindione derivatives @ in the @ heart @ and blood vessels domain
CR20110527A CR20110527A (es) 2009-04-09 2011-10-06 Derivados de 1-alquil-cinolin-4(1h)-ona, su preparación y su aplicación en terapéutica
NI201100180A NI201100180A (es) 2009-04-09 2011-10-06 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona
DO2011000306A DOP2011000306A (es) 2009-04-09 2011-10-06 Aplicaciones terapeuticas en el dominio cardiovascular de derivados de quinazolinadiona
CL2011002525A CL2011002525A1 (es) 2009-04-09 2011-10-07 Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular.
TNP2011000506A TN2011000506A1 (fr) 2009-04-09 2011-10-07 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
US13/268,371 US8846654B2 (en) 2009-04-09 2011-10-07 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
CO11132796A CO6440577A2 (es) 2009-04-09 2011-10-07 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona
HK12106684.4A HK1165997A1 (zh) 2009-04-09 2012-07-09 喹唑啉二酮衍生物在心血管領域的治療應用
HRP20150106TT HRP20150106T1 (hr) 2009-04-09 2015-01-28 Terapijska primjena derivata kinazolindiona u kardiovaskularnom podruäśju
CY20151100141T CY1115987T1 (el) 2009-04-09 2015-02-12 Θεραπευτικες εφαρμογες στον καρδιαγγειακο τομεα των παραγωγων κιναζολινεδιονης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0901755A FR2944206B1 (fr) 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Publications (2)

Publication Number Publication Date
FR2944206A1 FR2944206A1 (fr) 2010-10-15
FR2944206B1 true FR2944206B1 (fr) 2012-12-28

Family

ID=41181038

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0901755A Expired - Fee Related FR2944206B1 (fr) 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Country Status (35)

Country Link
US (1) US8846654B2 (zh)
EP (1) EP2416777B1 (zh)
JP (1) JP5685578B2 (zh)
KR (1) KR101686267B1 (zh)
CN (1) CN102458409B (zh)
AR (1) AR076232A1 (zh)
AU (1) AU2010233596B2 (zh)
BR (1) BRPI1010256A2 (zh)
CA (1) CA2758234A1 (zh)
CL (1) CL2011002525A1 (zh)
CO (1) CO6440577A2 (zh)
CR (1) CR20110527A (zh)
CY (1) CY1115987T1 (zh)
DK (1) DK2416777T3 (zh)
DO (1) DOP2011000306A (zh)
EA (1) EA020984B1 (zh)
EC (1) ECSP11011377A (zh)
ES (1) ES2528633T3 (zh)
FR (1) FR2944206B1 (zh)
HK (1) HK1165997A1 (zh)
HR (1) HRP20150106T1 (zh)
HU (1) HUE024161T2 (zh)
IL (1) IL215610A (zh)
MA (1) MA33254B1 (zh)
MX (1) MX2011010645A (zh)
NI (1) NI201100180A (zh)
NZ (1) NZ595660A (zh)
PL (1) PL2416777T3 (zh)
PT (1) PT2416777E (zh)
SG (2) SG175131A1 (zh)
SI (1) SI2416777T1 (zh)
TN (1) TN2011000506A1 (zh)
TW (1) TWI457330B (zh)
UY (1) UY32555A (zh)
WO (1) WO2010116090A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
EP2854780B1 (en) 2012-06-05 2017-08-30 University Of Kansas Inhibitors of respiratory syncytial virus
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879393A (en) * 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
JPS56164172A (en) * 1980-05-22 1981-12-17 Masayuki Ishikawa Novel 2,4 1h,3h -quinazolinedione derivative
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
EP1080069B1 (en) 1998-04-20 2003-03-19 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
WO2001044228A2 (fr) 1999-12-14 2001-06-21 Sanofi-Synthelabo Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
KR20070107099A (ko) 2005-03-01 2007-11-06 화이자 리미티드 신경병증성 통증의 치료를 위한 ｐｄｅ7 억제제의 용도
WO2007067946A2 (en) 2005-12-07 2007-06-14 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (cll)
NZ580413A (en) 2007-03-27 2012-11-30 Omeros Corp The use of pde7 inhibitors for the treatment of movement disorders
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
FR2921926B1 (fr) 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione

Also Published As

Publication number Publication date
HRP20150106T1 (hr) 2015-05-08
SG175131A1 (en) 2011-11-28
DOP2011000306A (es) 2011-10-31
ECSP11011377A (es) 2011-11-30
US20120184522A1 (en) 2012-07-19
PL2416777T3 (pl) 2015-05-29
AU2010233596A1 (en) 2011-11-03
NZ595660A (en) 2013-03-28
CN102458409A (zh) 2012-05-16
EP2416777A1 (fr) 2012-02-15
KR20120005499A (ko) 2012-01-16
WO2010116090A1 (fr) 2010-10-14
MX2011010645A (es) 2012-01-19
AU2010233596B2 (en) 2016-06-23
ES2528633T3 (es) 2015-02-11
SI2416777T1 (sl) 2015-02-27
JP2012523398A (ja) 2012-10-04
IL215610A (en) 2013-07-31
CN102458409B (zh) 2014-06-18
SG10201400420PA (en) 2014-05-29
TWI457330B (zh) 2014-10-21
EA020984B1 (ru) 2015-03-31
DK2416777T3 (en) 2015-02-09
IL215610A0 (en) 2011-12-29
BRPI1010256A2 (pt) 2016-03-22
PT2416777E (pt) 2015-02-04
AR076232A1 (es) 2011-05-26
HUE024161T2 (hu) 2016-02-29
FR2944206A1 (fr) 2010-10-15
CL2011002525A1 (es) 2012-02-17
HK1165997A1 (zh) 2012-10-19
UY32555A (es) 2010-11-30
CO6440577A2 (es) 2012-05-15
US8846654B2 (en) 2014-09-30
MA33254B1 (fr) 2012-05-02
NI201100180A (es) 2012-01-11
TN2011000506A1 (fr) 2013-05-24
CY1115987T1 (el) 2017-01-25
CR20110527A (es) 2014-05-12
EP2416777B1 (fr) 2014-11-12
EA201171229A1 (ru) 2012-12-28
TW201040155A (en) 2010-11-16
JP5685578B2 (ja) 2015-03-18
KR101686267B1 (ko) 2016-12-13
CA2758234A1 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
SMT201600098B (it) Antagonisti del complemento e loro usi
BR112013015592A8 (pt) derivados de biciclo-[3.2.1]-octilamida e usos dos mesmos
BRPI1010881A2 (pt) derivados de triazina e suas aplicações terapêuticas.
BRPI1010882A2 (pt) derivados de triazina e suas aplicações terapêuticas.
DK2172241T3 (da) Udbøjeligt kateter med forbundet midterstiver
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
DK3335709T3 (da) Gamma-hydroxybutyratsammensætninger og deres anvendelse til behandling af lidelser
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
FR2943673B1 (fr) Applications therapeutiques de derives de quinazolinedione
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI1011527A2 (pt) derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI1015471A2 (pt) ativador de gel relaxante
DK2318378T3 (da) Quinazolin-derivater
FR2944282B1 (fr) Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
BRPI1011318A2 (pt) derivados de triazina e suas aplicações terapêuticas
FR2944206B1 (fr) Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
DK2405910T3 (da) Rosuvastatin- og atorvastatinderivater
BRPI1011320A2 (pt) derivados de estiril-triazina e suas aplicações terapêuticas
FR2967672B1 (fr) Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
SMT201500123B (it) Dosaggio unitario di apadenoson
DK2392329T3 (da) Sammensætninger til anvendelse i behandling af myelodysplastisk syndrom
BRPI0908673A2 (pt) Conjunto de moléculas antiangiogênicas e seu uso.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20161230